Australia and New Zealand Prothrombin Complex Concentrate Market to Reach USD 40.4 Million By 2027; Stoked by Rising Bleeding Disorders Worldwide

The Australia and New Zealand prothrombin complex concentrate market size is expected to gain momentum by reaching USD 40.4 million by 2027. This is attributable to increasing prevalence of bleeding disorders that is likely to boost the adoption of advanced prothrombin complex concentrates in Australia and New Zealand. This information is published by Fortune Business Insights in its latest report, titled, “Australia and New Zealand Prothrombin Complex Concentrate Market Size, Share & Covid-19 Impact Analysis, By Product (4-factor PCC and 3-factor PCC), By Application (Acquired Coagulation Factor Deficiency and Congenital Coagulation Factor Deficiency and By End User (Hospitals & Ambulatory Surgical Centers, Specialty Clinics, and Others), 2020-2027.” The report further observes that the market stood at USD 17.8 million in 2019 and is projected to exhibit an impressive CAGR of 10.9% between 2020 and 2027.

Grifols Secures FDA Approval for New Consolidated Manufacturing Facility to Develop Recombinant Proteins

Several companies are trying to leverage the lucrative opportunities presented by the market for prothrombin complex concentrate in Australia and New Zealand by either developing advanced solutions or expanding their facilities. Among these companies, Grifols, a global healthcare provider, designed, built, and validated a state-of-the-art biological manufacturing facility with an investment of about USD 80 million. Additionally, the company secured the U.S. Food and Drug Administration (FDA) approval to shift prevailing immunodiagnostic manufacturing operations to this new consolidated manufacturing facility (CMF) located in California. This marks a significant event in the history of the company that focuses on expanding its product portfolio and further gaining a strong footprint.

To get a detailed report summary and research scope of this market, click here:

https://www.fortunebusinessinsights.com/australia-and-new-zealand-prothrombin-complex-concentrate-market-104761

Increasing Incidence of Bleeding Disorders to Feed Market Growth

According to the American Journal of Managed Care (AJMC), around 1,125,000 men are diagnosed with inherited bleeding disorder across the globe. The increasing prevalence of blood disorder is expected to boost the adoption of advanced prothrombin complex concentrates in Australia and New Zealand that are widely used to reverse the effects of congenital bleeding disorders. Additionally, supportive government policies to promote awareness is expected to bode well for the Australia and New Zealand prothrombin complex concentrate market growth during the forecast period.

Significant Investment by Prominent Companies to Brighten Their Market Prospects

The market for Australia and New Zealand prothrombin complex concentrate comprises small, medium, and large companies focusing on investing in R&D activities to develop novel solutions catering to the healthcare demand on a larger scale. Furthermore, other key players are adopting strategies such as collaborations and partnerships to gain a market stronghold and further expand their global footprint during the forecast period.

Industry Development:

• July 2019 – Portola Pharmaceuticals announced the presentation of a new in vitro data demonstration informing that the four-factor prothrombin complex concentrates (4F-PCCS) have no direct effect on inhibition of thrombin generation by factor XA inhibitors.

List of the Companies Operating in the Market for Australia and New Zealand Prothrombin Complex Concentrate

• CSL Limited (Melbourne, Australia)


• Grifols, S.A. (Barcelona, Spain) 


• Octapharma AG (Lachen, Switzerland)


• Kedrion S.p.A (Lucca, Italy)


• Sanquin (Amsterdam, The Netherlands)


• Takeda Pharmaceutical Company Limited (Mumbai, India)


• Other Prominent Players

Further Report Findings:

• The Australia and New Zealand prothrombin complex concentrate market stood at USD 17.8 million in 2019 and is expected to experience significant growth in the forthcoming years. This is attributable to the rising number of healthcare clinics in the countries between 2020 and 2027.


• Based on end-user, the hospitals and ambulatory surgical centers segment is expected to experience exponential growth in the forthcoming years. This is ascribable to factors such as the increasing number of invasive surgeries that is likely to propel the demand for advanced prothrombin complex concentrates in Australia and New Zealand.

Table of Segmentation: